MEP0908A - Derivati pirimidina za tretman neprirodnog rasta ćelija - Google Patents

Derivati pirimidina za tretman neprirodnog rasta ćelija

Info

Publication number
MEP0908A
MEP0908A MEP-09/08A MEP0908A MEP0908A ME P0908 A MEP0908 A ME P0908A ME P0908 A MEP0908 A ME P0908A ME P0908 A MEP0908 A ME P0908A
Authority
ME
Montenegro
Prior art keywords
treatment
cell growth
abnormal cell
pyrimidine derivatives
mammals
Prior art date
Application number
MEP-09/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Joel Thomas Arcari
Samit Kumar Bhattacharya
Arthur Douglas Brosius
Michael Joseph Luzzio
Kendra Louise Nelson
Gonghua Pan
James Alfred Southers Jr
Donn Gregory Wishka
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MEP0908A publication Critical patent/MEP0908A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
MEP-09/08A 2005-12-21 2006-12-11 Derivati pirimidina za tretman neprirodnog rasta ćelija MEP0908A (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75270805P 2005-12-21 2005-12-21
PCT/IB2006/003655 WO2007072158A2 (en) 2005-12-21 2006-12-11 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
MEP0908A true MEP0908A (xx) 2010-02-10

Family

ID=38038639

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-09/08A MEP0908A (xx) 2005-12-21 2006-12-11 Derivati pirimidina za tretman neprirodnog rasta ćelija

Country Status (30)

Country Link
US (1) US7820648B2 (es)
EP (1) EP1966207A2 (es)
JP (1) JP4332590B2 (es)
KR (1) KR101060051B1 (es)
CN (1) CN101346380B (es)
AP (1) AP2008004488A0 (es)
AR (1) AR058399A1 (es)
AU (1) AU2006327871A1 (es)
BR (1) BRPI0620324A2 (es)
CA (1) CA2634646C (es)
CR (1) CR10095A (es)
DO (1) DOP2006000289A (es)
EA (1) EA014551B1 (es)
EC (1) ECSP088563A (es)
GT (1) GT200600517A (es)
HN (1) HN2006042221A (es)
IL (1) IL191555A0 (es)
MA (1) MA30075B1 (es)
ME (1) MEP0908A (es)
NL (1) NL2000375C2 (es)
NO (1) NO20082338L (es)
PE (1) PE20071138A1 (es)
RS (1) RS20080272A (es)
SV (1) SV2008002969A (es)
TN (1) TNSN08270A1 (es)
TW (1) TW200736258A (es)
UA (1) UA89123C2 (es)
UY (1) UY30051A1 (es)
WO (1) WO2007072158A2 (es)
ZA (1) ZA200804488B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1656372T3 (pl) 2003-07-30 2013-08-30 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
CA2654670A1 (en) * 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh New compounds
EP2222647B1 (en) 2006-10-23 2015-08-05 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
CN103951658B (zh) 2007-04-18 2017-10-13 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
CN101903357A (zh) * 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
JP2011505407A (ja) * 2007-12-03 2011-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 過剰な又は異常な細胞増殖を特徴とする疾患を治療するためのジアミノピリジン
WO2009115583A1 (en) * 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Regioselective preparation of substituted pyrimidines
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
CA2726508C (en) 2008-06-17 2016-06-07 Astrazeneca Ab Pyridine compounds
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
JP5539518B2 (ja) 2009-08-14 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アミノ−５−トリフルオロメチルピリミジン誘導体の位置選択的調製
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
KR20130031296A (ko) 2010-05-21 2013-03-28 케밀리아 에이비 신규한 피리미딘 유도체
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
EP2646448B1 (en) 2010-11-29 2017-08-30 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
US9458154B2 (en) 2011-12-09 2016-10-04 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2013092854A1 (en) 2011-12-23 2013-06-27 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
CN103655577A (zh) * 2012-09-20 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103664957A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN105130907B (zh) * 2015-07-29 2018-10-16 沈阳药科大学 嘧啶类化合物及其用途
DK3484528T3 (da) 2016-07-18 2021-02-15 Janssen Pharmaceutica Nv Tau-pet-billeddannelsesligander
WO2020023851A1 (en) * 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
JP2024502174A (ja) * 2021-01-07 2024-01-17 オンタリオ・インスティテュート・フォー・キャンサー・リサーチ（オーアイシーアール） Ｎｕａｋキナーゼの阻害剤としてのチエニル及びシクロアルキルアミノピリミジン化合物、その組成物及び使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
DE602004022633D1 (de) * 2003-01-30 2009-10-01 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
BRPI0510963A (pt) * 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
CA2566707A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
JP4332590B2 (ja) 2009-09-16
ZA200804488B (en) 2009-05-27
AP2008004488A0 (en) 2008-06-30
CN101346380B (zh) 2012-02-29
EA014551B1 (ru) 2010-12-30
HN2006042221A (es) 2010-01-18
DOP2006000289A (es) 2007-07-31
UA89123C2 (ru) 2009-12-25
KR20080077026A (ko) 2008-08-20
NL2000375A1 (nl) 2007-06-25
US7820648B2 (en) 2010-10-26
GT200600517A (es) 2007-09-13
MA30075B1 (fr) 2008-12-01
WO2007072158A8 (en) 2008-08-14
JP2009520807A (ja) 2009-05-28
EA200801287A1 (ru) 2008-10-30
IL191555A0 (en) 2008-12-29
TNSN08270A1 (fr) 2009-10-30
BRPI0620324A2 (pt) 2011-11-08
ECSP088563A (es) 2008-07-30
PE20071138A1 (es) 2007-12-29
WO2007072158A2 (en) 2007-06-28
CA2634646A1 (en) 2007-06-28
TW200736258A (en) 2007-10-01
CN101346380A (zh) 2009-01-14
US20080234303A1 (en) 2008-09-25
NO20082338L (no) 2008-06-25
CR10095A (es) 2008-07-17
KR101060051B1 (ko) 2011-08-29
UY30051A1 (es) 2007-07-31
EP1966207A2 (en) 2008-09-10
AU2006327871A1 (en) 2007-06-28
AR058399A1 (es) 2008-01-30
WO2007072158A3 (en) 2007-12-27
NL2000375C2 (nl) 2008-01-03
CA2634646C (en) 2012-04-10
SV2008002969A (es) 2010-08-17
RS20080272A (en) 2009-07-15

Similar Documents

Publication Publication Date Title
MEP0908A (xx) Derivati pirimidina za tretman neprirodnog rasta ćelija
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
TW200612949A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MY148636A (en) Benzimidazole derivatives
TNSN06074A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
EA200601796A1 (ru) Пиримидиновые производные для лечения аномального клеточного роста
MX2009011090A (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
MX2007013624A (es) Inhibidores de proteina cinasa.
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
WO2007044724A3 (en) Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
WO2011027249A3 (en) Benzimidazole derivatives
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2007122634A3 (en) Pyrimidinediones as tyrosine kinase inhibitors
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
WO2006129168A3 (en) Bicyclic derivatives for the treatment of abnormal cell growth
WO2009008345A1 (ja) 金属錯体化合物、これを有効成分とする癌治療剤組成物および該金属錯体化合物用の中間体
WO2008106125A3 (en) Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
MY153733A (en) Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
UA93313C2 (en) Benzimidazole derivatives
CR20240216A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno